CYP1A2 and chronic kidney disease: Newly approved and limited data available. From SKYLIGHT 1 trial, treatment-emergent adverse reactions included headache and a small number of participants with abnormal ALT or AST.167 It is recommended to measure liver enzyme levels at baseline and monthly for the first 3 months, then at months 6 and 9 following initiation of treatment.168Contraindications: avoid in patients with cirrhosis, severe renal impairment, or end stage renal disease.Drug interactions—Fezolinetant is metabolized by CYP1A2 and should be avoided in patients on CYP1A2 inhibitors169